Objective. To review the drugs commercially available at present and in the near future in relation to the evolution ofAlzheimerdisease,bearinginmindthepossiblepsychiatricdisorderswhichmaybeassociatedwiththedisease.Development.Thetherapeuticapproachisplannedaccordingtothedifferentphasesofthedisease.Inthepreclinicalphase,anti-inflammatory drugs and estrogens in post-menopausal women have been effective. In the initial phase current recognition therapy is directed basically towards correcting the break-down of acetylcholine (tacrine, donepezil, SB202026, SDZ ENA 713). For depressive symptoms serotonin levels are corrected using selective inhibitors of serotonin uptake. Conclusions. Drug treatment should be considered with the association of drugs which activate the malfunctioning circuits and/or pathways. It would also be useful to design clinical studies using pharmacological combinations of cholinergic agonists, estrogens, anti-inflammatory drugs, seli-giline and/or new anti-cholinesterase drugs amongst others